New York Oncology Hematology — Albany, New York

Public research footprint of New York Oncology Hematology, compiled from the ClinicalTrials.gov public registry.

239

Registered studies

Active

Recruiting now

138

Completed

Stopped or withdrawn

Most-studied conditions

Non-small Cell Lung Cancer · Stage IV Cutaneous Melanoma AJCC v6 and v7 · Recurrent Melanoma · Stage IIIB Cutaneous Melanoma AJCC v7

Recently updated registry entries

NCT04613596 — Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase… (Recruiting)
NCT01274338 — Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage… (Active Not Recruiting)
NCT05753501 — Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves… (Active Not Recruiting)

7 more recent registry entries at this facility

Enter your work email to view the full list.

I’d also like to receive occasional marketing emails from Eichor for research sites (optional — unsubscribe anytime).

Work at New York Oncology Hematology?

Verify and correct how your facility appears in public registry records — free.

Verify this profile →

Compiled from public registry records (ClinicalTrials.gov) as of August 05, 2026. Counts reflect how this facility appears in registry listings; name variants may exist and are not combined. This page describes public records only and makes no assessment of any facility.